ViewRay moves HQ to Denver

August 10, 2022
by Thomas Dworetzky, Contributing Reporter
ViewRay, which designs, manufactures, and markets the MRIdian radiation therapy system, is moving its HQ to Denver from Oakwood Village, Ohio.

The Denver office opened in mid-2019, and has grown from an initial staff of 10 people to 50 "with the expansion of the company's international marketing, finance and legal teams," the company said in a statement.

"ViewRay is excited that Colorado will be the international headquarters for this innovative cancer therapy. The state is a magnet for talented professionals and academics in our field and is fast becoming a center of the international bioscience industry," said ViewRay president and CEO Scott Drake.

The Oakwood Village facility will remain and focus on product development and customer and physician training, the company told the Cleveland Business Journal.

The MRIdian system permits anatomical visualization through diagnostic-quality MR images. This lets oncologists adapt a radiation therapy plan that has tight treatment margins to avoid unnecessary radiation exposure of surrounding healthy organs and tissue — in five or fewer treatment sessions, and without implanted markers.

In late July, the company announced that Saitama Medical University International Medical Center in Japan has bought a MRIdian system for its newly built comprehensive cancer center in Yamane, Hidaka City. Plans call for the first patient treatments beginning in early 2023.

“Our focus on high-quality medical treatment with an emphasis on patient safety and satisfaction makes MRIdian a perfect addition to our cancer treatment offerings,” said Dr. Shingo Kato, professor, and director, Department of Radiation Oncology. “The ability to visualize and track the tumor and control the beam in real time under MR guidance, and adapt the treatment delivery to the unique anatomical and tumor changes within each patient, fully supports our patient-centered approach to care and will be of significant benefit to patients throughout the region.”

Additional installations are on book for Centre Oscar Lambret in Lille, France; the VA Ann Arbor Healthcare System at the Lieutenant Colonel Charles S. Kettles VA Medical Center; and the Shin-Matsudo Central General Hospital's Shin-Matsudo Accuracy Radiation Therapy Center in Japan's Toukatsu area.

In June, Detroit-based Henry Ford Health became the first MRIdian center in the world to complete a full course of patient treatments using the new MRIdian A3i System.

The new MRIdian A3i features enable Henry Ford clinicians to collaborate simultaneously and connect remotely during patient treatment.

“People worldwide travel to Henry Ford Health for advanced cancer treatment, and our MRIdian systems have allowed us to deliver expedited treatment courses often completed in one to two weeks,” director of MR-guided Radiation and GI Radiation at the Henry Ford Cancer Institute, Dr. Parag Parikh said in a statement. “As the first cancer center in the world to treat patients with the MRIdian A3i, we have observed the improved accuracy of a liver tumor treatment using its two-plane imaging, and the technology has already assisted with treatment planning and evaluation for a patient with recurrent meningioma.”

When ViewRay supplied the United Kingdom's GenesisCare with its first MRIdian system in 2018, Aldo Rolfo, executive manager for GenesisCare Europe, said in a statement that, “combining an MR scanner with a linear accelerator is the way of the future in radiotherapy, allowing us to see — for the first time — what's really happening inside the body during treatment.”

The integration of MR technology, radiation delivery, and proprietary software to locate, target and track the position and shape of tumors while radiation is delivered, he noted, “will enable our clinicians to offer truly personalized radiotherapy by adapting treatment in real time, to better target tumors and minimize side effects for patients.”